1. Home
  2. ACRV vs DSX Comparison

ACRV vs DSX Comparison

Compare ACRV & DSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • DSX
  • Stock Information
  • Founded
  • ACRV 2018
  • DSX 1999
  • Country
  • ACRV United States
  • DSX Greece
  • Employees
  • ACRV N/A
  • DSX N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • DSX Marine Transportation
  • Sector
  • ACRV Health Care
  • DSX Consumer Discretionary
  • Exchange
  • ACRV Nasdaq
  • DSX Nasdaq
  • Market Cap
  • ACRV 203.9M
  • DSX 231.6M
  • IPO Year
  • ACRV 2022
  • DSX 2005
  • Fundamental
  • Price
  • ACRV $6.60
  • DSX $1.87
  • Analyst Decision
  • ACRV Strong Buy
  • DSX Hold
  • Analyst Count
  • ACRV 5
  • DSX 1
  • Target Price
  • ACRV $22.40
  • DSX $3.00
  • AVG Volume (30 Days)
  • ACRV 63.5K
  • DSX 1.2M
  • Earning Date
  • ACRV 11-13-2024
  • DSX 11-25-2024
  • Dividend Yield
  • ACRV N/A
  • DSX 12.70%
  • EPS Growth
  • ACRV N/A
  • DSX N/A
  • EPS
  • ACRV N/A
  • DSX 0.05
  • Revenue
  • ACRV N/A
  • DSX $231,152,000.00
  • Revenue This Year
  • ACRV N/A
  • DSX N/A
  • Revenue Next Year
  • ACRV N/A
  • DSX $15.89
  • P/E Ratio
  • ACRV N/A
  • DSX $40.82
  • Revenue Growth
  • ACRV N/A
  • DSX N/A
  • 52 Week Low
  • ACRV $3.19
  • DSX $1.73
  • 52 Week High
  • ACRV $11.90
  • DSX $3.22
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 42.20
  • DSX 38.05
  • Support Level
  • ACRV $6.56
  • DSX $1.82
  • Resistance Level
  • ACRV $7.45
  • DSX $1.94
  • Average True Range (ATR)
  • ACRV 0.47
  • DSX 0.06
  • MACD
  • ACRV -0.00
  • DSX 0.01
  • Stochastic Oscillator
  • ACRV 28.12
  • DSX 35.29

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About DSX Diana Shipping inc. common stock

Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation, the services provided by the vessels are similar and all operate under the same economic environment.

Share on Social Networks: